The Implementation of FDG PET/CT for Staging Bladder Cancer: Changes in the Detection and Characteristics of Occult Nodal Metastases at Upfront Radical Cystectomy?

Occult lymph node (LN)-metastases are frequently found after upfront radical cystectomy (uRC) for bladder cancer (BC). We evaluated whether the implementation of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG PET/CT) influenced nodal staging at uRC. All consecutive BC patients who underwent uRC with bilateral pelvic lymph node dissection (PLND) were identified and divided into two cohorts: cohort A consisted of patients staged with FDG PET/CT and contrast-enhanced CT (CE-CT) (2016–2021); cohort B consisted of patients staged with CE-CT only (2006–2011). The diagnostic performance of FDG PET/CT was assessed and compared with that of CE-CT. Thereafter, we calculated the occult LN metastases proportions for both cohorts. In total, 523 patients were identified (cohort A n = 237, and cohort B n = 286). Sensitivity, specificity, PPV and NPV of FDG PET/CT for detecting LN metastases were 23%, 92%, 42%, and 83%, respectively, versus 15%, 93%, 33%, 81%, respectively, for CE-CT. Occult LN metastases were found in 17% of cohort A (95% confidence interval (CI) 12.2–22.8) and 22% of cohort B (95% CI 16.9–27.1). The median size of LN metastases was 4 mm in cohort A versus 13 mm in cohort B. After introduction of FDG PET/CT, fewer and smaller occult LN metastases were present after uRC. Nevertheless, up to one-fifth of occult (micro-)metastases were still missed.

[1]  R. Meijer,et al.  Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy. , 2022, European urology.

[2]  V. Brouste,et al.  Impact of 18 FDG- PET CT in the Management of Muscle Invasive Bladder Cancer. , 2022, Clinical genitourinary cancer.

[3]  H. G. van der Poel,et al.  Staging 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Changes Treatment Recommendation in Invasive Bladder Cancer. , 2021, European urology oncology.

[4]  H. G. van der Poel,et al.  18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer. , 2020, Current opinion in urology.

[5]  J. Witjes,et al.  European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. , 2020, European urology.

[6]  P. D. Di Paolo,et al.  Utility of Routine Preoperative 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18F-FDG PET/CT) in Identifying Pathologic Lymph Node Metastases at Radical Cystectomy. , 2020, The Journal of urology.

[7]  C. Radulescu,et al.  Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer , 2019, European Radiology.

[8]  K. Aben,et al.  Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3‐4aN0M0 compared to cT2N0M0 bladder cancer , 2018, International journal of cancer.

[9]  Søren Høyer,et al.  Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Results from a High-volume Centre Including Long-term Follow-up. , 2017, European urology focus.

[10]  W. Horninger,et al.  Pelvic Lymph Node Staging by Combined 18F‐FDG‐PET/CT Imaging in Bladder Cancer Prior to Radical Cystectomy , 2017, Clinical genitourinary cancer.

[11]  M. Mazumdar,et al.  Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  I. Shabo,et al.  PET/CT versus conventional CT for detection of lymph node metastases in patients with locally advanced bladder cancer , 2015, BMC Urology.

[13]  C. Radulescu,et al.  Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  P. Dasgupta,et al.  Role of fluorodeoxyglucose positron emission tomography (FDG PET)‐computed tomography (CT) in the staging of bladder cancer , 2014, BJU international.

[15]  W. Meinhardt,et al.  Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone , 2014, BJU international.

[16]  J. Cheville,et al.  Eligibility for neoadjuvant/adjuvant cisplatin‐based chemotherapy among radical cystectomy patients , 2014, BJU international.

[17]  W. Meinhardt,et al.  Differences in histopathological evaluation of standard lymph node dissections result in differences in nodal count but not in survival , 2013, World Journal of Urology.

[18]  K. Renaudin,et al.  F-fluorodeoxyglucose positron emission tomography–computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: A prospective study , 2013 .

[19]  R. Wahlqvist,et al.  Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. , 2012, European urology.

[20]  H. G. van der Poel,et al.  Standard lymph node dissection for bladder cancer: significant variability in the number of reported lymph nodes. , 2012, The Journal of urology.

[21]  G. Sonpavde,et al.  A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. , 2011, The Lancet. Oncology.

[22]  O. Akin,et al.  Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Maes,et al.  FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. , 2010, European urology.

[24]  Cary Siegel,et al.  Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Coleman,et al.  Recommendations on the Use of 18F-FDG PET in Oncology , 2008, Journal of Nuclear Medicine.

[26]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Altman,et al.  Statistics Notes: Diagnostic tests 1: sensitivity and specificity , 1994 .

[28]  R L Wahl,et al.  Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.